Fly News Breaks for February 14, 2020
Feb 14, 2020 | 07:51 EDT
Guggenheim analyst Christopher Pasquale said DexCom's Q4 report "caps off a truly impressive 2019 for the company. Expecting a repeat of that performance in 2020 is "probably unrealistic," but he still sees a long growth runway as CGM adoption continues to ramp and the company branches out into other patient groups, Pasquale tells investors.He increased his price target on DexCom shares to $300 from $245 and reiterates a Buy rating on the stock after earnings.
News For DXCM From the Last 2 Days
There are no results for your query DXCM